Teprotumumab – Medxy AI

Teprotumumab Versus Intravenous Glucocorticoids in Thyroid Eye Disease: Insights from a Japanese MRI Study

By MedXY 08/26/2026

This study evaluates teprotumumab's effectiveness for thyroid eye disease in Japanese patients, revealing notable improvements in orbital inflammation and proptosis compared to intravenous glucocorticoid therapy with distinct MRI-based anatomical effects.

Diabetes & Endocrinology news Ophthalmology

Teprotumumab for Thyroid Eye Disease Carries a Measurable Long-Term Dysglycemia Risk

By MedXY 05/03/2026

A large multinational cohort study found that teprotumumab use in thyroid eye disease was associated with higher risks of prediabetes, diabetes, and antidiabetes medication initiation over 5 years.

Clinical Updates Diabetes & Endocrinology news Ophthalmology Specialties

Veligrotug Emerges as a Promising Therapy for Thyroid Eye Disease: Insights from the THRIVE and THRIVE-2 Trials

By MedXY 07/31/2025

Veligrotug demonstrates robust efficacy and manageable safety in both active and chronic thyroid eye disease, positioning itself as a potential alternative to teprotumumab based on phase 3 THRIVE trial data.